Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): Results of a phase II study

J. W. Valle; A. Dangoor; J. Beech; D. J. Sherlock; S. M. Lee; J. H. Scarffe; R. Swindell; M. Ranson

doi:10.1038/sj.bjc.6602394

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): Results of a phase II study

J. W. Valle, A. Dangoor, J. Beech, D. J. Sherlock, S. M. Lee, J. H. Scarffe, R. Swindell, M. Ranson

Research output: Contribution to journal › Article › peer-review

Abstract

Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m -2, although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months. © 2005 Cancer Research UK.

Original language	English
Pages (from-to)	628-630
Number of pages	2
Journal	British Journal of Cancer
Volume	92
Issue number	4
DOIs	https://doi.org/10.1038/sj.bjc.6602394
Publication status	Published - 28 Feb 2005

Keywords

Hepatocellular carcinoma
Pegylated liposomal doxorubicin
Phase II

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6602394

Cite this

@article{c03d6da2f8cd4f1689f12abaa60d6ee3,

title = "Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): Results of a phase II study",

abstract = "Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m -2, although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months. {\textcopyright} 2005 Cancer Research UK.",

keywords = "Hepatocellular carcinoma, Pegylated liposomal doxorubicin, Phase II",

author = "Valle, {J. W.} and A. Dangoor and J. Beech and Sherlock, {D. J.} and Lee, {S. M.} and Scarffe, {J. H.} and R. Swindell and M. Ranson",

year = "2005",

month = feb,

day = "28",

doi = "10.1038/sj.bjc.6602394",

language = "English",

volume = "92",

pages = "628--630",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "4",

}

TY - JOUR

T1 - Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): Results of a phase II study

AU - Valle, J. W.

AU - Dangoor, A.

AU - Beech, J.

AU - Sherlock, D. J.

AU - Lee, S. M.

AU - Scarffe, J. H.

AU - Swindell, R.

AU - Ranson, M.

PY - 2005/2/28

Y1 - 2005/2/28

N2 - Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m -2, although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months. © 2005 Cancer Research UK.

AB - Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m -2, although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months. © 2005 Cancer Research UK.

KW - Hepatocellular carcinoma

KW - Pegylated liposomal doxorubicin

KW - Phase II

U2 - 10.1038/sj.bjc.6602394

DO - 10.1038/sj.bjc.6602394

M3 - Article

SN - 0007-0920

VL - 92

SP - 628

EP - 630

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 4

ER -

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): Results of a phase II study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this